DUBLIN–(BUSINESS WIRE)–The “Bone Marrow Transplant Rejection – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Bone Marrow Transplant Rejection – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews the key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 11, 38, 17, 3, 44, 7 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.
Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Key Topics Covered:
Introduction
- Bone Marrow Transplant Rejection – Overview
- Bone Marrow Transplant Rejection – Therapeutics Development
Bone Marrow Transplant Rejection – Therapeutics Assessment
Bone Marrow Transplant Rejection – Companies Involved in Therapeutics Development
- Bone Marrow Transplant Rejection – Drug Profiles
Bone Marrow Transplant Rejection – Dormant Projects
- Bone Marrow Transplant Rejection – Discontinued Products
- Bone Marrow Transplant Rejection – Product Development Milestones
Appendix
Companies Mentioned
- AbbVie Inc
- Adienne Pharma & Biotech
- AltruBio Inc
- Amgen Inc
- AnaptysBio Inc
- apceth Biopharma GmbH
- ASC Therapeutics Inc
- AstraZeneca Plc
- Athersys Inc
- Autolus Therapeutics Plc
- Bellicum Pharmaceuticals Inc
- Biocon Ltd
- Biogen Inc
- BioIncept LLC
- BioTheryX Inc
- BlueRock Therapeutics
- Boryung ViGenCell Inc
- Bristol-Myers Squibb Co
- Capricor Therapeutics Inc
- Cell Source Inc
- Cellect Biotechnology Ltd
- Cellective BioTherapy Inc
- Cellix Bio Pvt Ltd
- CheckPoint Immunology Inc
- Chipscreen Biosciences Ltd
- Clinigen Group Plc
- Compugen Ltd
- CSL Ltd
- CTI BioPharma Corp
- Cytodyn Inc
- Cytopeutics Pte Ltd
- Daewoong Pharmaceutical Co Ltd
- Dualogics Corp
- Educell doo
- Eli Lilly and Co
- enGene Inc
- Enlivex Therapeutics Ltd
- Evive Biotech
- ExCellThera Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fujifilm Holdings Corp
- GigaGen Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Glia LLC
- Humanigen Inc
- iCELL Biotechnology Co Ltd
- Immplacate
- Immune Modulation Inc
- ImmuneTarget Inc
- Imstem Biotechnology Inc
- Incyte Corp
- Inspyr Therapeutics Inc
- ITB-Med AB
- Jazz Pharmaceuticals Plc
- JN Biosciences LLC
- Kadmon Corp LLC
- Kalytera Therapeutics Inc
- Kamada Ltd
- Kiadis Pharma NV
- Kiniksa Pharmaceuticals Ltd
- Kymab Ltd
- LG Chem Ltd
- MaaT Pharma
- Machavert Pharmaceuticals LLC
- Magenta Therapeutics Inc
- Mallinckrodt Plc
- Medac Pharma Inc
- Medicenna Therapeutics Corp
- Mediolanum farmaceutici SpA
- Medsenic SAS
- Mereo Biopharma Group Plc
- Mesoblast Ltd
- Millennium Pharmaceuticals Inc
- MitoImmune Therapeutics Inc
- NapaJen Pharma Inc
- Neovii Pharmaceuticals AG
- Nurix Therapeutics Inc
- OncoImmune Inc
- OSE Immunotherapeutics
- Panorama Research Inc
- Pfizer Inc
- Pharmicell Co Ltd
- Platinum Biotech (Beijing) Co Ltd
- Pluristem Therapeutics Inc
- Precision Biosciences Inc
- REGiMMUNE Corp
- SCM lifescience Co Ltd
- Seattle Genetics Inc
- Secura Bio Inc
- Seres Therapeutics Inc
- STERO Biotechs Ltd
- StingInn LLC
- Suzhou Connect Biopharmaceuticals Ltd
- Syndax Pharmaceuticals Inc
- Synthetic Biologics Inc
- Takeda Pharmaceutical Co Ltd
- Targazyme Inc
- TCF GmbH
- TeraImmune Inc
- TGV Laboratories Inc
- United BioPharma Inc
- Vault Pharma Inc
- VBI Vaccines Inc
- Visterra Inc
- Xenikos BV
- Xenothera SAS
- XL-protein GmbH
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tcfj2o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900